Clinical Trial Update: Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sitagliptin for prevention of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Sherif S. Farag | Conditions: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2020-12-29